Literature DB >> 6206136

1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation.

A K Bhalla, E P Amento, B Serog, L H Glimcher.   

Abstract

The proliferative response of murine spleen and thymus cells to antigen but not to lectin was inhibited by the active metabolite of vitamin D3, 1,25-(OH)2D3. To directly examine the effect of 1,25-(OH)2D3 on T cell activation in the absence of other complicating interactions, we utilized a panel of cloned Ia-restricted T cell hybridomas that secrete IL 2 on activation by cloned Ia-bearing stimulator cells (TA3) or when stimulated by mitogen. Physiologic concentrations of 1,25-(OH)2D3 (0.01 to 0.1 nm) inhibited the antigen-induced secretion of IL 2 by several of these T cell hybridomas. This inhibition was dependent on the concentration of the free hormone and could be overcome by increasing the number of Ia-bearing stimulator cells used. Pretreatment of the T hybridoma but not the TA3 stimulator cell with 1,25-(OH)2D3 resulted in inhibition of activation. These results are consistent with the finding that specific 1,25-(OH)2D3 receptors are present on the T cell hybridomas but are lacking in TA3 cells. 1,25-(OH)2D3 failed, however, to inhibit the activation of the T cell hybridomas by lectin or by an anti-Thy-1 antibody. These findings suggest that 1,25-(OH)2D3 may be interfering with early events of antigen-induced T cell activation, perhaps by hindering T cell recognition of the relevant antigen on stimulator cell surfaces. This system should prove useful in studying the molecular mechanisms by which 1,25-(OH)2D3 acts to inhibit T cell activation and subsequent IL 2 production.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206136

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  97 in total

1.  Vitamin D Levels in Takayasu's Arteritis and a Review of the Literature on Vasculitides.

Authors:  Fatma Alibaz-Oner; Özlem Asmaz-Haliloglu; Dilek Gogas-Yavuz; Meryem Can; Goncagul Haklar; Haner Direskeneli
Journal:  J Clin Lab Anal       Date:  2015-12-10       Impact factor: 2.352

Review 2.  Hormones and the immune response.

Authors:  A K Bhalla
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

3.  In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway.

Authors:  Hang Wang; Jianmin Wang; Hua Qu; Huili Wei; Baolan Ji; Zesong Yang; Jing Wu; Qin He; Yuanyuan Luo; Dan Liu; Yang Duan; Fang Liu; Huacong Deng
Journal:  Endocrine       Date:  2016-07-09       Impact factor: 3.633

Review 4.  MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer.

Authors:  Tahseen H Nasti; Laura Timares
Journal:  Photochem Photobiol       Date:  2014-11-07       Impact factor: 3.421

Review 5.  Dendritic cells: potential triggers of autoimmunity and targets for therapy.

Authors:  J A Hardin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

6.  Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin.

Authors:  Bryan R Becklund; Donald W Hansen; Hector F Deluca
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

Review 7.  Mycobacterium tuberculosis, autoimmunity, and vitamin D.

Authors:  Yinon Shapira; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 8.  Vitamin D signaling, infectious diseases, and regulation of innate immunity.

Authors:  John H White
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 9.  T cell replicative senescence in human aging.

Authors:  Jennifer P Chou; Rita B Effros
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India.

Authors:  Neetu Israni; Ravinder Goswami; Avinash Kumar; Rajni Rani
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.